Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder

Ane Korff, Xiaojing Yang, Ozan Ozdemir, Ananya Samanta, Yong-Dong Wang, Tushar Patni, Alfonso J. Lav / science - Science Translational Medicine, Volume 18, Issue 846, April 2026.

AI Summary: Researchers report that antisense oligonucleotide therapy reversed neurological deficits in mouse models of HNRNPH2‑related neurodevelopmental disorder. The preclinical results provide a targeted mechanism to correct pathogenic RNA processing, moving a once‑untreatable condition toward a plausible therapeutic path — pending the usual caution about translating mice to humans.

#pharmaceuticals #biotech #drugdevelopment #infanthealth #behavioralhealth #genetherapy #genetics

Children with rare debilitating brain diseases suffer from mutations in a little-known protein complex

23 days / medicalxpress

Low overlap of plasma and CSF protein quantitative trait loci affects protein discovery for neurological disease

4 wks / science / Daniel Western, Chengran Yang, Jigyasha Timsina, Menghan Liu, Ciyang Wang, Meghan C. Campbell, Paul

Cancer cells can rewrite RNA messages, creating new drug targets in aggressive tumors

4 wks / medicalxpress

Antisense oligonucleotide strategy reverses HNRNPH2-related neurodevelopmental disorder

5 wks / medicalxpress

Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder

5 wks / science / Ane Korff, Xiaojing Yang, Ozan Ozdemir, Ananya Samanta, Yong-Dong Wang, Tushar Patni, Alfonso J. Lav

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Rural Health, Pediatric Oncology, Cybersecurity, Health Disparities and look for the RSS link.

StackHealth Time Machine

More StackHealth